SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial - Concepedia

Concepedia

Publication | Open Access

SER-109, an Investigational Microbiome Drug to Reduce Recurrence After <i>Clostridioides difficile</i> Infection: Lessons Learned From a Phase 2 Trial

DOI Full Paper Access

150

Citations

34

References

2020

Year

Barbara McGovern, Christopher B. Ford, Matthew R. Henn, Darrell S. Pardi, Sahil Khanna, Elizabeth Hohmann, Edward J. O’Brien, Christopher A. Desjardins, Patricia Bernardo, Jennifer R. Wortman,

Clinical Infectious Diseases

Abstract

NCT02437487, https://clinicaltrials.gov/ct2/show/NCT02437487?term=SER-109&draw= 2&rank=4.

References

	Year	Citations

Page 1